This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Probst-Hensch, N. M. Articles by Yu, M. C. Search for Related Content PubMed PubMed Citation Articles by Probst-Hensch, N. M. Articles by Yu, M. C.

N-Acetyltransferase 2 Phenotype but not NAT1*10 Genotype Affects Aminobiphenyl-Hemoglobin Adduct Levels¹

Institute of Social and Preventive Medicine of the University of Basel, CH-4051 Basel, Switzerland [N. M. P-H.]; Department of Preventive Medicine, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90033-0800 [R. K. R., M. C. Y.]; Division of Toxicology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 [P. L. S., S. R. T.]; Laboratory of Computational Biology and Risk Analysis, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709 [D. A. B., M. A. W.]; and the Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 [K. K. C.]

Aminobiphenyls (ABPs) in tobacco have been implicated in bladder cancer etiology in smokers. N-Acetylation of ABPs in the liver, predominantly by the N-acetyltransferase 2 (NAT2) isozyme, represents a detoxification pathway, whereas O-acetylation of N-hydroxy-ABPs in the bladder, predominantly by the N-acetyltransferase 1 (NAT1) isozyme, represents a bioactivation pathway. We and others have demonstrated that NAT2 phenotype affects 3- and 4-ABP-hemoglobin adduct levels (higher levels in slow acetylators), which are considered valid biomarkers of the internal dose of ABP to the bladder. We have also shown that NAT1 genotype (NAT1*10 allele) is associated with increased DNA adduct levels in urothelial tissue and higher risk of bladder cancer among smokers. It is not known whether NAT1*10 genotype influences ABP-hemoglobin adduct levels. Therefore, we assessed 403 primarily non-Hispanic white residents of Los Angeles County for their NAT2 acetylator phenotype, NAT1*10 acetylator genotype, and 3- and 4-ABP-hemoglobin adduct levels. Eighty-two subjects were current tobacco smokers of varying intensities. Tobacco smokers had significantly higher mean 3- and 4-ABP-hemoglobin adduct levels relative to nonsmokers. The levels increased with increased amounts smoked per day (two-sided, P < 0.0001 in all cases). With adjustment for NAT1 genotype and race, the smoking-adjusted geometric mean level of 3-ABP-hemoglobin adducts in NAT2 slow acetylators was 47% higher than that in NAT2 rapid acetylators (P = 0.01). The comparable value for 4-ABP-hemoglobin adducts was 17% (P = 0.02). In contrast, no association between NAT1*10 genotype and 3- or 4 ABP-hemoglobin adduct levels was observed after adjustment for NAT2 phenotype, smoking, and race. The present study suggests that the impact of the NAT1*10 genotype on 3- and 4-ABP-hemoglobin adducts is noninformative on the possible association between NAT1 activity and bladder cancer risk.

This article has been cited by other articles:

				J.-M. Yuan, K. K. Chan, G. A. Coetzee, J.E. Castelao, M. A. Watson, D. A. Bell, R. Wang, and M. C. Yu Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer Carcinogenesis, July 1, 2008; 29(7): 1386 - 1393. [Abstract] [Full Text] [PDF]

				Y. Zang, M. A. Doll, S. Zhao, J. C. States, and D. W. Hein Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2 Carcinogenesis, August 1, 2007; 28(8): 1665 - 1671. [Abstract] [Full Text] [PDF]

				L. Airoldi, P. Vineis, A. Colombi, L. Olgiati, C. Dell'Osta, R. Fanelli, L. Manzi, F. Veglia, H. Autrup, A. Dunning, et al. 4-Aminobiphenyl-Hemoglobin Adducts and Risk of Smoking-Related Disease in Never Smokers and Former Smokers in the European Prospective Investigation into Cancer and Nutrition Prospective Study Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2118 - 2124. [Abstract] [Full Text] [PDF]

				J. Gan, P. L. Skipper, M. Gago-Dominguez, K. Arakawa, R. K. Ross, M. C. Yu, and S. R. Tannenbaum Alkylaniline-Hemoglobin Adducts and Risk of Non-Smoking-Related Bladder Cancer J Natl Cancer Inst, October 6, 2004; 96(19): 1425 - 1431. [Abstract] [Full Text] [PDF]

				P. L. Skipper, S. R. Tannenbaum, R. K. Ross, and M. C. Yu Nonsmoking-related Arylamine Exposure and Bladder Cancer Risk Cancer Epidemiol. Biomarkers Prev., June 1, 2003; 12(6): 503 - 507. [Abstract] [Full Text] [PDF]

				D. H. Phillips Smoking-related DNA and protein adducts in human tissues Carcinogenesis, December 1, 2002; 23(12): 1979 - 2004. [Abstract] [Full Text] [PDF]

				L. Airoldi, F. Orsi, C. Magagnotti, R. Coda, D. Randone, G. Casetta, M. Peluso, A. Hautefeuille, C. Malaveille, and P. Vineis Determinants of 4-aminobiphenyl-DNA adducts in bladder cancer biopsies Carcinogenesis, May 1, 2002; 23(5): 861 - 866. [Abstract] [Full Text] [PDF]